Press releases

21/12/21 - 11:07

2022 Annual Calendar of Corporate Events (296.13 KB)

Other

Download

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)

Products Molecular

Download

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)

Products Immunodiagnostic

Download

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)

Products Immunodiagnostic

Download

05/11/21 - 11:22

Weekly report treasury shares buy-back (2.15 MB)

Other

Download

02/11/21 - 20:00

Conclusion treasury shares buy-back plan (294.67 KB)

Other

Download

02/11/21 - 19:57

Weekly report treasury shares buy-back (3.5 MB)

Other

Download

27/10/21 - 16:35

Issuance of the "Physical Settlement Notice" (517.5 KB)

Other

Download

07/10/21 - 11:45

Publication of the summary report of the votes (290.08 KB)

Other

Download

04/10/21 - 12:27

The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)

Other

Download

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)

Products Molecular

Download

30/07/21 - 18:43

Start up of the treasury shares buy-back plan (773.96 KB)

Other

Download

22/07/21 - 18:28

Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)

Other

Download

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)

Products Immunodiagnostic

Download

07/06/21 - 15:16

Communication on total amount of voting rights (563.42 KB)

Other

Download

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)

Products Immunodiagnostic

Download

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)

Products Molecular

Download

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)

Products Immunodiagnostic

Download

22/04/21 - 15:58

Shareholders' meeting April 22, 2021 (422.91 KB)

Other

Download

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)

Products Immunodiagnostic

Download

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)

Products Immunodiagnostic

Download

14/04/21 - 10:05

Communication voting rights amount (544.6 KB)

Other

Download

12/04/21 - 11:08

Weekly report treasury shares buy-back (914.42 KB)

Other

Download

06/04/21 - 8:53

Start up buy-back plan (774.02 KB)

Other

Download

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)

Products Immunodiagnostic

Download

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)

Products Immunodiagnostic

Download

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)

Products Immunodiagnostic

Download

27/01/21 - 18:50

2021 Annual Calendar of Corporate Events (209.87 KB)

Other

Download

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)

Products Immunodiagnostic

Download

Press releases

Select by year

Select category

2022 Annual Calendar of Corporate Events (296.13 KB)

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)

Weekly report treasury shares buy-back (2.15 MB)

Conclusion treasury shares buy-back plan (294.67 KB)

Weekly report treasury shares buy-back (3.5 MB)

Issuance of the "Physical Settlement Notice" (517.5 KB)

Publication of the summary report of the votes (290.08 KB)

The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)

Start up of the treasury shares buy-back plan (773.96 KB)

Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)

Communication on total amount of voting rights (563.42 KB)

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)

Shareholders' meeting April 22, 2021 (422.91 KB)

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)

Communication voting rights amount (544.6 KB)

Weekly report treasury shares buy-back (914.42 KB)

Start up buy-back plan (774.02 KB)

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)

2021 Annual Calendar of Corporate Events (209.87 KB)

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)

Price Sensitive